U.K. cost watchdogs nix Dendreon's Provenge; GSK's Slaoui joins IAVI board;

> The U.K.'s cost watchdogs have deemed Dendreon's ($DNDN) cancer vaccine Provenge too expensive for coverage on England's National Health Service. Report

> GlaxoSmithKline ($GSK) Global Vaccines Chairman Moncef Slaoui has joined the board of directors of the International AIDS Vaccine Initiative (IAVI). Release

> Sanofi Pasteur is planning a large-scale renovation project that will include construction of a new quality control building, set to begin early this year. Report

> San Diego, CA-based biotech Polynoma has launched a Phase III trial of its melanoma vaccine candidate. More

And Finally... Influenza vaccination may protect against Guillain-Barre syndrome, a new study suggests. More (reg. req.)

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.